Chiquita Brooks-LaSure would be in a key position to implement the Biden Administration’s drug pricing priorities and is familiar with the balancing act needed when considering competing interests among stakeholders as policies are shaped.
President Biden’s choice as administrator of the Centers for Medicare and Medicaid Services is reportedly Chiquita Brooks-LaSure, a former official at the Health and Human Services Department and CMS under the Obama Administration who played key roles in implementing the coverage expansion and insurance reforms mandated by the Affordable Care Act.
Brooks-LaSure served as deputy director for policy and regulation at the CMS Center for Consumer Information and Insurance Oversight from...
Highlights from Day Three of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for the FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.
Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.
Pink Sheet reporter and editors discuss the potential impact of the Most-Favored Nation drug pricing proposal on Europe, the United States, as well as the pharmaceutical industry.
Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.
Key expert panel go-ahead with a trial waiver put’s Eisai's Alzheimer's therapy on track for a debut in India where tailored pricing will be pivotal. Lilly’s Kisunla is also under regulatory review.
Pink Sheet reporter and editors discuss the potential impact of the Most-Favored Nation drug pricing proposal on Europe, the United States, as well as the pharmaceutical industry.
